Concepedia

Nicole N. Davarpanah

NN

Statistics

Publications

17

Citations

1.8K

H-Index

15

Active since

2016

Affiliations

National Cancer Institute(Current)

Center for Cancer Research

The Ohio State University

Queen Mary University of London

Rutgers Cancer Institute

Nicole N. Davarpanah is an author at National Cancer Institute specializing in oncology, medicine, and pharmacology.

Publications per year

2016–2023

17

Publications

17

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

Thomas Powles, Zoe J. Assaf, Nicole N. Davarpanah et al. · Nature · 2021 · 604 citations

, , +12

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

Joaquim Bellmunt, Maha Hussain, Jürgen E. Gschwend et al. · The Lancet Oncology · 2021 · 412 citations · Full text

, , +12

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Andrea B. Apolo, Rosa Nadal, Daniel M. Girardi et al. · Journal of Clinical Oncology · 2020 · 137 citations · Full text

, , +12

Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma

Thomas Powles, Zoe J. Assaf, Viraj Degaonkar et al. · European Urology · 2023 · 131 citations

, , +16

Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial

Andrea B. Apolo, Rosa Nadal, Yusuke Tomita et al. · The Lancet Oncology · 2020 · 89 citations · Full text

, , +12

1–5 of 17